Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2739-2749

  Goode, E L ^a   Stanford, J L ^a   Peters, M A ^a   Janer, M ^a   Gibbs, M ^a   Kolb, S ^a   Badzioch, M D ^a   Hood, L ^a   Ostrander, E A ^a   Jarvik, G P ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CHROMOSOMAL LOCALIZATION; DISEASE MARKER; FAMILIAL CANCER; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; FAMILY HEALTH; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE (GENETICS); LOD SCORE; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0034813944     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Cancer statistics 2001
2. Epidemiology of prostatic cancer: A case-control study
3. Familial prostate cancer in Sweden. A nationwide register cohort study
4. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada
5. Mendelian inheritance of familial prostate cancer
6. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
7. V89L polymorphism of type 2,5-α reductase enzyme gene predicts prostate cancer presence and progression
8. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
9. Prostate cancer associated with CYP17 genotype
10. Glutathione S-transferase-μ (GSTMI), and -θ (GSTTI) genotypes in the etiology of prostate cancer
11. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
12. Vitamin D receptor polymorphisms and lethal prostate cancer
13. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
14. A candidate prostate cancer susceptibility gene at chromosome 17p.
15. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
16. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance
17. Evidence for autosomal dominant inheritance of prostate cancer
18. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer
19. Autosomal dominant inheritance of prostate cancer: A confirmatory study
20. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
21. Predisposing gene for early-onset prostate cancer, localized on chromosome lq42.2-43
22. A genome screen of multiplex prostate cancer sibships
23. A genomic scan of prostate cancer families identifies multiple regions of interest
24. Evidence for a prostate cancer-susceptibility locus on chromosome 20
25. Genomewide scan for prostate cancer-aggressiveness loci
26. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4
27. Current status of linkage studies in hereditary prostate cancer
28. Genetics of prostate cancer: Too many loci, too few genes
29. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at lq24-25
30. Re: Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
31. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
32. Linkage analysis of chromosome lq markers in 136 prostate cancer families
33. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees
34. Linkage analyses at the chromosome 1 loci 1q24-25 (HPCl), lq42.2-43 (PCAP), and lp36 (CAPB) in families with hereditary prostate cancer
35. Replication linkage study for prostate cancer susceptibility genes
36. Linkage analysis of 150 high-risk prostate cancer families at lq24-25
37. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer
38. Regression models for linkage heterogeneity applied to familial prostate cancer
39. Combined analysis of hereditary prostate cancer linkage to lq24-25: Results from 772 families from the International Consortium for Prostate Cancer Genetics
40. Evidence for a prostate cancer susceptibility locus on the X chromosome
41. Evidence for a rare prostate cancer-susceptibility locus at chromosome lp36
42. Analysis of chromosome lq42.2-43 in 152 families with high risk prostate cancer
43. No evidence of linkage for chromosome lq42.2-43 in prostate cancer
44. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin
45. Genetic linkage analysis of prostate cancer families to Xq27-28
46. Suggestive evidence for a site-specific prostate cancer gene on chromosome lp36
47. No evidence of linkage to chromosome lq42.2-43 in 131 prostate cancer families from the ACTANE consortium
48. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe
49. Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer
50. Analysis of Human Genetic Linkage, Ed. 3
51. Confirmation of prostate cancer susceptibility genes using high risk families. monograph on innovative study designs and analytical approaches to the genetic epidemiology of cancer
52. LOD score analysis
53. Linkage of early-onset familial breast cancer to chromosome 17q21
54. BRCAI mutations in primary breast and ovarian carcinomas
55. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI
56. Complete genomic screen in late-onset familial alzheimer disease. Evidence for a new locus on chromosome 12
57. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
58. Histologic grading and clinical staging of prostatic carcinoma
59. Management of prostate malignancy
60. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: Results from the population based prostate cancer outcomes study
61. Statistical considerations when assessing outcomes following treatment for prostate cancer
62. The present status of radical prostatectomy for stages A and B prostatic cancer
63. Strategies for characterizing highly polymorphic markers in human gene mapping
64. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPCI) on chromosome 1
65. Avoiding recomputation in linkage analysis
66. Faster sequential genetic linkage computations
67. Linkage probability and its approximate confidence interval under possible heterogeneity
68. Parametric and nonparametric linkage analysis: A unified multipoint approach
69. Efficient multipoint linkage analysis through reduction of inheritance space
70. Allele-sharing models: LOD scores and accurate linkage tests
71. A class of tests for linkage using effected pedigree members
72. Prostate cancer linkage to HPCI: Effect of year of diagnosis
73. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy
74. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens
75. Prostate biopsy interpretation. Current concepts, 1999
76. Staging prostate cancer-1997: Current methods and limitations
77. Diagnosis, management and screening of early localized prostate cancer
78. An Alu polymorphism intragenic to the neurofibromatosis type 1 gene (NFI)
79. A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer
80. Pathological features of hereditary prostate cancer
81. Clinical and pathological features of hereditary prostate cancer
82. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor
83. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy
84. Hereditary prostate cancer: Epidemiologic and clinical features
85. Genetic epidemiology of prostate cancer in the utah mormon genealogy
86. Family history of prostate cancer in patients with localized prostate cancer: An independent predictor of treatment outcome
87. Familial prostate cancer: A different disease?
88. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
89. Prostate cancer potentially linked to the HPC1 gene
90. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer
91. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results
92. Genetic dissection of complex traits
93. Genetic dissection of complex traits
94. Thresholds and sample sizes
95. Significance levels in complex inheritance